Back to Awarded Treatment Trials
Awarded Trial: 01T-418
Grant ID
01T-418
Illness
Schizophrenia
Primary Drug/Intervention
Celecoxib
Primary Dosage
400 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Müller
Sample Size
40
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANSS, SANS, CBI, ESRS, Barnes Akathisia, Quality of Life
Results
In a randomized, double-blind study, celecoxib (400mg/day) given adjunctively to risperidone (2-6 mg per day), was studied in 40 patients with schizophrenia. There was no significant difference between placebo and celecoxib observed with PANSS ratings of psychopathology, in contrast to an earlier study performed by this group. In a post-hoc analysis, patients with a duration of illness less than 2 years may have experienced a salutory effect of celecoxib treatment.
Publication
N/A
Link
N/A
PI Name
Norbert Müller
Degree
MD
Center
Department of Psychiatry
Institution
Ludwig-Maximilians Universitaet
Address
Nussbaumstr. 7
City or Town
Munich
State or Province
N/A
Zip or Postal Code
80336
Country
Germany
Email Address
norbert.mueller@med.uni-muenchen.de